Biomarkers of Bone Remodeling in Children with Mucopolysaccharidosis Types I, II, and VI

Overview

Journal J Pediatr Rehabil Med

Publisher Sage Publications

Specialties Pediatrics
Rehabilitation Medicine

Date 2014 Aug 7

PMID 25096868

Citations 15

Authors

David A Stevenson

Kyle Rudser

Alicia Kunin-Batson

Ellen B Fung

David Viskochil

Elsa Shapiro

Paul J Orchard

Chester B Whitley

Lynda E Polgreen

Affiliations

Soon will be listed here.

Abstract

Purpose: Skeletal disease causes significant morbidity in mucopolysaccharidoses (MPS), and bone remodeling processes in MPS have not been well characterized. The objective of this study was to determine if biomarkers of bone turnover are abnormal in children with specific MPS disorders (i.e. MSP-I, MPS-II, and MPS-VI) compared to healthy children.

Methods: A cross-sectional study was performed of serum biomarkers of bone formation (bone-specific alkaline phosphatase [BSAP], osteocalcin) and urine biomarkers of bone resorption (pyridinoline, deoxypyridinoline) in MPS and healthy controls. Measures of physical function and pain were obtained using the Children's Health Questionnaire (CHQ).

Results: The cohort consisted of 39 children with MPS (MPS-I=26; MPS-II=11; MPS-VI=4) and 51 healthy children. Adjusting for sex and Tanner stage group, MPS individuals had statistically significant increases for osteocalcin (p< 0.001), with trends toward higher BSAP (p=0.054) and urinary pyridinoline (p=0.084). These biomarkers were not significantly associated with CHQ bodily pain and physical-function scores.

Conclusion: Osteocalcin was increased in children with MPS disorders, with trends for increases in BSAP and urinary pyridinoline, suggesting that bone remodeling is altered in children with MPS. Future studies to assess the ability of these biomarkers to quantify and monitor MPS skeletal disease in response to therapy are needed.

Citing Articles

Bone Remodeling in an Mps-1h Girl after Hematopoietic Stem Cell Transplantation along with Enzymatic Replacement Therapy.

Tummolo A, Brunetti G, Piacente L, Marzollo A, Biffi A, Burlina A Endocr Metab Immune Disord Drug Targets. 2022; 22(14):1425-1432.

PMID: 35619307 DOI: 10.2174/1871530322666220520121839.

Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases.

Rintz E, Higuchi T, Kobayashi H, Galileo D, Wegrzyn G, Tomatsu S Mol Ther Methods Clin Dev. 2022; 24:71-87.

PMID: 34977274 PMC: 8688940. DOI: 10.1016/j.omtm.2021.11.007.

Bone Biomarkers in Mucopolysaccharidoses.

Nakamura-Utsunomiya A Int J Mol Sci. 2021; 22(23).

PMID: 34884458 PMC: 8658023. DOI: 10.3390/ijms222312651.

Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.

Peck S, Lau Y, Kang J, Lin M, Arginteanu T, Matalon D Mol Genet Metab. 2021; 133(4):378-385.

PMID: 34154922 PMC: 8289741. DOI: 10.1016/j.ymgme.2021.06.005.

Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.

Lund T, Doherty T, Eisengart J, Freese R, Rudser K, Fung E JIMD Rep. 2021; 58(1):89-99.

PMID: 33728251 PMC: 7932872. DOI: 10.1002/jmd2.12190.

References

Muenzer J, Beck M, Eng C, Escolar M, Giugliani R, Guffon N . Multidisciplinary management of Hunter syndrome. Pediatrics. 2009; 124(6):e1228-39. DOI: 10.1542/peds.2008-0999. View

Muenzer J, Wraith J, Clarke L . Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009; 123(1):19-29. DOI: 10.1542/peds.2008-0416. View

Simonaro C, Ge Y, Eliyahu E, He X, Jepsen K, Schuchman E . Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A. 2009; 107(1):222-7. PMC: 2806747. DOI: 10.1073/pnas.0912937107. View

Polgreen L, Tolar J, Plog M, Himes J, Orchard P, Whitley C . Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(12):1005-11. DOI: 10.1038/bmt.2008.20. View

Russell C, Hendson G, Jevon G, Matlock T, Yu J, Aklujkar M . Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet. 1998; 53(5):349-61. DOI: 10.1111/j.1399-0004.1998.tb02745.x. View

Petryk A, Bergemann T, Polga K, Ulrich K, Raatz S, Brown D . Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2005; 91(3):899-905. DOI: 10.1210/jc.2005-1927. View

Rimoin D, SILBERBERG R, Hollister D . Chondro-osseous pathology in the chondrodystrophies. Clin Orthop Relat Res. 1976; (114):137-52. View

Sandstedt E, Fasth A, Eek M, Beckung E . Muscle strength, physical fitness and well-being in children and adolescents with juvenile idiopathic arthritis and the effect of an exercise programme: a randomized controlled trial. Pediatr Rheumatol Online J. 2013; 11(1):7. PMC: 3614532. DOI: 10.1186/1546-0096-11-7. View

Silveri C, Kaplan F, Fallon M, Bayever E, August C . Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop Relat Res. 1991; (269):305-11. View

10.

Polgreen L, Thomas W, Fung E, Viskochil D, Stevenson D, Steinberger J . Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom. 2013; 17(1):200-6. PMC: 3872499. DOI: 10.1016/j.jocd.2013.03.004. View

11.

Guarany N, Schwartz I, Guarany F, Giugliani R . Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med. 2012; 5(1):37-46. DOI: 10.3233/PRM-2012-0194. View

12.

Valayannopoulos V, Nicely H, Harmatz P, Turbeville S . Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010; 5:5. PMC: 2873242. DOI: 10.1186/1750-1172-5-5. View

13.

Malm G, Gustafsson B, Berglund G, Lindstrom M, Naess K, Borgstrom B . Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr. 2008; 97(8):1108-12. DOI: 10.1111/j.1651-2227.2008.00811.x. View

14.

Pastores G . Musculoskeletal complications encountered in the lysosomal storage disorders. Best Pract Res Clin Rheumatol. 2008; 22(5):937-47. DOI: 10.1016/j.berh.2008.09.005. View

15.

Fung E, Johnson J, Madden J, Kim T, Harmatz P . Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI. J Pediatr Rehabil Med. 2010; 3(1):13-23. PMC: 2898152. View

16.

Wrotniak B, Schall J, Brault M, Balmer D, Stallings V . Health-related quality of life in children with sickle cell disease using the child health questionnaire. J Pediatr Health Care. 2012; 28(1):14-22. PMC: 4479286. DOI: 10.1016/j.pedhc.2012.09.004. View

17.

Tolar J, Grewal S, Bjoraker K, Whitley C, Shapiro E, Charnas L . Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2007; 41(6):531-5. DOI: 10.1038/sj.bmt.1705934. View

18.

Auclair D, Ketteridge D, Oates S, Hopwood J, Byers S . An overview of intra-articular therapy for mucopolysaccharidosis VI. J Pediatr Rehabil Med. 2011; 3(1):3-6. DOI: 10.3233/PRM-2010-0101. View

19.

Wang R, Bodamer O, Watson M, Wilcox W . Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011; 13(5):457-84. DOI: 10.1097/GIM.0b013e318211a7e1. View

20.

Apaz M, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira Sato J, Marcantoni M . Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum. 2009; 61(4):509-17. DOI: 10.1002/art.24343. View